Pharming Group NV Q4 2024 Earnings Report
Key Takeaways
Pharming's Q4 2024 revenue increased by 14% year-over-year to $92.7 million, with RUCONEST® revenue rising 9% and Joenja® revenue surging 66%. Operating profit grew significantly, reflecting strong product performance and increased patient enrollments. The company continued investments in research and acquisitions to expand its rare disease portfolio.
Total revenue increased 14% YoY to $92.7 million.
RUCONEST® revenue rose 9% to $79.6 million, while Joenja® revenue surged 66% to $13.1 million.
Operating profit jumped to $6.7 million from $1.1 million in Q4 2023.
Net income reached $3.7 million, reversing a loss of $3.1 million in Q4 2023.
Pharming Group NV
Pharming Group NV
Pharming Group NV Revenue by Segment
Pharming Group NV Revenue by Geographic Location
Forward Guidance
Pharming expects continued growth driven by RUCONEST® and Joenja®, with expansion into new markets and additional regulatory approvals in 2025.
Positive Outlook
- Projected total revenue between $315 million and $335 million for 2025.
- Increased Joenja® patient enrollment and global expansion efforts.
- Further regulatory approvals for leniolisib in Japan and pediatric indications.
- Advancement of Phase II trials for primary immunodeficiencies.
- Completion of the Abliva acquisition to strengthen the rare disease portfolio.
Challenges Ahead
- Potential fluctuations in quarterly revenue due to product launches.
- Higher research and development costs from clinical trial expansions.
- Regulatory uncertainties in multiple global markets.
- Macroeconomic conditions affecting healthcare spending.
- Integration costs associated with the Abliva acquisition.
Revenue & Expenses
Visualization of income flow from segment revenue to net income